Who are Endocrine therapy combined with trastuzumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/endocrine-therapy-combined-with-trastuzumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Endocrine therapy combined with trastuzumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endocrine therapy combined with trastuzumab (Endocrine therapy combined with trastuzumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: endocrine agent + HER2-targeted monoclonal antibody. Area: Oncology.

phase 3 Combination therapy: endocrine agent + HER2-targeted monoclonal antibody Estrogen receptor (ER) and HER2 (human epidermal growth factor receptor 2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Endocrine therapy combined with trastuzumab (Endocrine therapy combined with trastuzumab) — Sun Yat-sen University. This combination therapy blocks estrogen receptor signaling while simultaneously inhibiting HER2-mediated growth pathways in hormone receptor-positive, HER2-positive breast cancer.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Endocrine therapy combined with trastuzumab TARGET	Endocrine therapy combined with trastuzumab	Sun Yat-sen University	phase 3	Combination therapy: endocrine agent + HER2-targeted monoclonal antibody	Estrogen receptor (ER) and HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: endocrine agent + HER2-targeted monoclonal antibody class)

Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Endocrine therapy combined with trastuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/endocrine-therapy-combined-with-trastuzumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab